RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
Repligen Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Repligen(RGEN.US), With a Forecast Between $160 to $200
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), SAGE Therapeutics (SAGE) and Repligen (RGEN)
Repligen's Fair Valuation and Cautious Growth Outlook Lead to Hold Rating
Express News | Repligen Corp : RBC Cuts Target Price to $189 From $202
JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $190
Repligen Analyst Ratings
Repligen | 10-Q: Q1 2025 Earnings Report
Wolfe Research Upgrades Repligen to Outperform From Peerperform
Repligen Targets 10% to 15% Growth in Proteins for 2025 Following New Resin Launches
Repligen's Strong Q1 Performance and Strategic Acquisition Justify Buy Rating
Repligen Corporation Reports Strong Q1 2025 Financial Results With 10% Revenue Growth and 72% Increase in Adjusted Operating Income
Repligen Corp Q1 Profit Increases, Beats Estimates
Express News | Repligen Corp: Working to Navigate Through Current Economic Environment and See Minimal Impact From Tariffs on EPS
Express News | Repligen Corp FY2025 Shr View $1.71, Rev View $700.4 Mln -- LSEG IBES Data
Express News | Repligen Corp: Reiterates 2025 Full Year Organic Revenue Guidance of 9.5% - 13.5%
Repligen | 8-K: Repligen Reports First Quarter 2025 Financial Results
Earnings Flash (RGEN) REPLIGEN CORPORATION Reports Q1 Revenue $169.2M, Vs. FactSet Est of $163.7M
Express News | Repligen Outlook FY Revenue USD 695-720 Million